Safety Data on Heated Vegetable Glycerin

MONQ uses USP (United States Pharmacopeia) grade vegetable-derived glycerin. Glycerin, also known as glycerol, is derived from plant or animal fats and is phosphorylated by glycerol-3-kinase to become glycerol-3-phosphate for entry into fatty acid metabolism.

Metabolism of glycerin occurs primarily in the liver (80%), but can occur in any cell as glycerol is a principle component of normal cell metabolism. The elimination of glycerin in humans follows zero order kinetics1, and the plasma t1/2 of glycerin is approximately 30 minutes (10min-50min)1 in humans. Between 40-79% of glycerin is converted to glucose2, with the remainder presumably transesterified into fat. The toxicity of glycerin is remarkably low across a broad range of animal models and in humans. Healthy humans tolerate doses of 2.2g/kg for 50 days with no observable adverse effects (NOEL)2. The total amount of glycerin consumed in a typical consumer vaporization device is <1mg per puff3–5. This represents a 1650-fold lesser amount than has been shown to be safe as the oral dose in humans, calculated from the following formula (2.2g/kg*75kg/person)/(100 puffs/day *.001g/puff). Because of the relatively low systemic exposure from vaporization devices, only the respiratory glycerin exposure will be considered for purposes of risk assessment.

Glycerin Vapor Inhalation:

Mechanics of Electronic Glycerin Vaporization Devices

In consumer vaporization devices, an 80% glycerin mixture is heated to a minimum of 132C6 at which point a combination of heat, negative pressure from inhalation, and turbulent airflow over the large surface area of wick filaments causes aerosolization and vaporization of the liquid. Exposure to glycerin vapor occurs primarily during inhalation and exhalation, which is called the “puff”, lasting between 1-3 seconds 3,4. Between each puff, there is an inter-puff interval, that lasts between 15s-60s (mean=23s)4,7 during which ambient air is inhaled that contains very little glycerin vapor relative to the concentration of the puff. This is due to simple gas diffusion mechanics and the relatively small volume of gas from the lung expanding into the vastly larger volume of the consumer’s environment. For the purposes of exposure calculations, only the concentration of glycerin vapor during the puff phase will be considered.

Animal Studies

Long term inhalation studies showed no evidence of toxicity 0.033mg/L and 0.165mg/L glycerol in rats8. Irritation was seen at 0.662mg/L of continuous glycerol vapor exposure for 6 hours per day8, which does not represent a feasible usage situation for humans3,7.

Human Studies

The National Institute for Occupational Safety and Health (NIOSH) and the Occupational Health Safety and Health Administration (OSHA) have established a permissible exposure limit (PEL) for aerosolized glycerin (mist) of 10mg/m3 and 5mg/m3 for total exposure and respiratory exposure, respectively6,7,9,10,11. For the purposes of assessing the relative risk of inhaled glycerin mist, the lower dose of 5mg/m3 will be considered. Importantly, the PEL of 5mg/m3 is a time weighted average (TWA) of exposure over an 8-hour workday. Researchers have shown that a recreational inhalant vaporization device can yield an acute glycerol concentration of 300-500mg/m3 from a single puff5 which superficially seems well above the NIOSH guidelines of 5mg/m3 . However, the exposure in a consumer vaporization device is mostly limited to the 1-3 seconds duration of each puff5 followed by a 15-60 sec (mean=23 sec) interval3, in which the glycerin concentration decreases immediately upon respiration. Because of the puff/inter-puff interval, 1 hour of continuous use of a typical vaporization device would result in less than 180 seconds of cumulative exposure. As a comparison , the workday used for NIOSH calculations10,11 is 28,800s (8hr) which is 160X the total exposure time (180s) in hour of continuous use. The time component of exposure is critical in accurately assessing exposure risk from inhaled glycerol.

Glycerin Exposure in MONQ

We adapted a simplified AUC model for total exposure (mg*s/l) to be more appropriate for aerosolized exposure and compensated for continuous (PEL) vs intermittent exposure (vaporizer use) assuming an immediate clearance upon exhalation.

Each puff of a MONQ yields an estimated 3-4mg glycerin based on: 800mg/device/200-300 puffs/device. The time of exposure is approximated at 1 sec exposure, with a 23 sec inter-puff interval, based on published models3,4. The volume of the sinuses, pharynx and upper trachea are estimated at 50 mL and will be used for exposure calculations.

dose (mg)

exposure time (min)

volume (m3)


fold exposure vs MONQ usage

Adverse event

MONQ recommended (10 puffs/day)







MONQ high usage (50 puffs/day)







Kienhaus et al














Renne et al low dose







Renne et al. highest dose







Propylene Glycol vs Glycerin:

Due to its lower boiling point and viscosity, and different solvent properties, propylene glycol is often mixed with glycerin in liquid blends intended for inhalation. However, in relation to glycerin, the safety profile of propylene glycol is less well established. Propylene glycol is known to cause irritation at high doses, but has not been shown to cause damage at low doses. It has also been noted that heating of propylene glycol can result in the production of formaldehyde and acetaldehyde.

Thermal Considerations and Carbonyls

The heating of glycerol has been shown to generate a wide range of carbonyl compounds, including formaldehyde, acrolein, and acetaldehyde. This process seems to be limited to temperatures in excess of 250C and high wattage in the context of ecig devices, where most of the current research has been done. MONQ uses a similar technology to aerosolize an 80% glycerin solution, with a 3.7V battery and a 2.5-3 ohm coil. Using Voltage2/resistance, the power output of the MONQ device is estimated at 4.5-5.4 watts.

Multiple studies have shown that no detectable amounts of carbonyls are produced from glycerin aerosolization at low power (5w) settings3,6. Using experimental values from Kienhuis5 which showed a time of exposure calculations from Fig 1, we estimated the total carbonyl exposure (mg*s/m3).

carbonyl exposure

Based on the routine safe use of glycerin in food and pharmaceuticals and on the published literature of inhalation of vaporized polyol carriers, the routine use of MONQ represents a risk that is 86-fold lower than NIOSH recommended exposure limits7 for irritation, and 200 fold lower than the NOEL in rodent experiments.

1. Ricci, Z. & Ronco, C. Year in review 2008: Critical Care – nephrology. Crit. Care 13, 227 (2009).

2. Robergs, R. A. & Griffin, S. E. Biochemistry , Pharmacokinetics and Clinical and Practical Applications. Sport. Med. 26, 145–167 (1998).

3. Farsalinos, K. E. & Polosa, R. Safety Evaluation and Risk Assessment of Electronic Cigarettes as Tobacco Cigarette Substitutes: A Systematic Review. Ther. Adv. Drug Saf. 5, 67–86 (2014).

4. Behar, R. R. Z. et al. Puffing topography and nicotine intake of electronic cigarette users. PLoS One 10, e0117222 (2015).

5. Kienhuis, A. S. et al. Potential harmful health effects of inhaling nicotine-free shisha-pen vapor: a chemical risk assessment of the main components propylene glycol and glycerol. Tob. Induc. Dis. 13, 15 (2015).

6. Geiss, O., Bianchi, I. & Barrero-Moreno, J. Correlation of volatile carbonyl yields emitted by e-cigarettes with the temperature of the heating coil and the perceived sensorial quality of the generated vapours. Int. J. Hyg. Environ. Health (2016). doi:10.1016/j.ijheh.2016.01.004

7. Farsalinos, K. E. & Baeyens, F. Harmful effects from one puff of shisha-pen vapor: methodological and interpretational problems in the risk assessment analysis. Tob. Induc. Dis. 14, 22 (2016).

8. Renne, R. A. et al. 2-Week and 13-Week Inhalation Studies of Aerosolized Glycerol in Rats. Inhal. Toxicol. 4, 95–111 (1992).

9. Hebbinghaus, H. et al. Gefahrstoffe- Reinhaltung der Luft. Gefahrstoffe- Reinhaltung der Luft 7–8, 299–307 (2014).

10. OSHA PEL Airborne Contaminant Calculation.

11. Eller, P. M. NIOSH manual of analytical methods. DIANE Publishing (1994).

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.